Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Cell sorting technology supports researchers advancing new therapies
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Subscribe To Our Newsletter & Stay Updated
